- Non-metastatic, high-grade osteosarcoma following surgical resection
- Used in combination with postoperative multi-agent chemotherapy
Dosage:
- 2 mg/m² intravenously, twice weekly for the first 12 weeks, then once weekly for an additional 24 weeks
- Total duration: 36 weeks (48 doses)
Dosage is based on body surface area (BSA)
- Lyophilized powder for IV infusion
- Each vial contains 4 mg of mifamurtide
- Administered via IV infusion over 1 hour
- Infusion should be started immediately after preparation
- Premedication with acetaminophen or NSAIDs may be considered to reduce fever and chills
- Class: Immunomodulator / Macrophage activator
- Mechanism of Action:
Mifamurtide activates monocytes and macrophages, stimulating production of cytokines (e.g., TNF-α, interleukins) that help destroy tumor cells, particularly osteosarcoma cells. - Half-life: ~2 hours
- Metabolism: Not well characterized; rapidly cleared from plasma
- Excretion: Likely via hepatic and renal mechanisms
- Fever, chills
- Fatigue
- Nausea, vomiting
- Headache
- Tachycardia
- Back or joint pain
- Hypersensitivity to mifamurtide or any component of the formulation
- Concurrent use with cyclosporine or other immunosuppressants
- Not to be used in patients with autoimmune disease or those receiving high-dose corticosteroids
- Immunosuppressants (e.g., cyclosporine, tacrolimus): ↓ efficacy of mifamurtide
- Corticosteroids: may interfere with immune activation; avoid concurrent high-dose use
- No known CYP450 interactions
Drug Status
Availability | |
Pregnancy | |
Breastfeeding | |
Schedule |
BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
---|---|---|---|---|---|
Mepact | 4mg | Injection | 1’s | Takeda France | Phillips Therapeutics |